Milestone Pharmaceuticals said on Friday the U.S. health regulator had declined to approve its nasal spray to treat a type of ...

PTC Therapeutics said on Friday the European Commission will remove its inherited progressive muscle-wasting disorder from the region after an advisory panel reaffirmed a negative opinion of the drug ...

The 'big three' insulin producers Novo Nordisk, Eli Lilly, and Sanofi are being sued by the state of California for allegedly working together to set artificially inflated prices for their products.

Novo Nordisk leads a GLP-1 agonist market that could surpass $150 billion by 2035. Ironically, the market is passing on the ...

Novo Nordisk may need to sue (and win) to remove these personalized ... GLP-1 agonists has attracted competition. Novo Nordisk, Eli Lilly, and other companies, including Pfizer, are developing ...

The regulator also fired a shot across the bows of insulin manufacturers like Eli Lilly, Novo Nordisk, and Sanofi, saying that the PBMs are "not the only potentially culpable actors" for driving ...

A European regulatory committee has rejected Eli Lilly’s U.S.-approved Alzheimer’s disease treatment over potentially ...

Berenberg Bank analyst Kerry Holford maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) on March 21 and set a price target of $970.00. The company’s shares closed last Friday at ...

Eli Lilly is expanding its menu of direct-to-consumer healthcare offerings. The Big Pharma announced Thursday that its LillyDirect platform will now connect U.S. users to both in-person and ...

The trial results are among the pharmaceutical industry's most critical and closely watched of the year, as they bring Eli Lilly's drug one step closer to becoming a new, needle-free alternative ...